Grunenthal GmbH - Strategic SWOT Analysis Review

Date: April 29, 2015
Pages: 34
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GD6EA62815FEN
Leaflet:

Download PDF Leaflet

Grunenthal GmbH - Strategic SWOT Analysis Review
Grunenthal GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

SCOPE
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief Summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
HIGHLIGHTS

Grunenthal GmbH (Grunenthal) is an international research-based pharmaceutical company. It holds expertise in the therapeutic area of pain. The company researches, develops, produces and markets a wide range of products for the treatment of pain and innovative formulations for established active substances. Some of the company’s key products include Versatis, Zaldiar, Palexia, Transtec, Tramal, Norspan, Recivit and Tapentadol, among others. It also develops solutions for the improved management of chronic pain. Grunenthal is the research-oriented pharmaceutical company with major investments in research and development. It markets its products in more than 155 countries and operates through its affiliates in 25 countries. Grunenthal is headquartered in Aachen, Germany.

The company focuses on becoming the patient-centric company in the field of pain and be a leader in therapy innovation. It plans to increase its engagement and investments in the development of new products. In line with this the company entered into a commercial collaboration agreement with AcelRx Pharmaceuticals, Inc., for the European Union commercialization of AcelRx's ZALVISO.

Grunenthal GmbH Key Recent Developments

Jul 09, 2013: Grünenthal Group selects Dotmatics’ data query, analysis and visualization suite for Discovery research scientists
Jun 20, 2013: Grunenthal Expands Use Of BioClinica's Next Generation Trident IWR/IVR For Global Trial
Apr 19, 2013: Grunenthal Highlights Significant R&D Advances In Pain, Inflammation And INTAC Tamper-Resistant Technology At 2013 BIO International Convention

REASONS TO BUY
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Grunenthal GmbH - Key Facts
Grunenthal GmbH - Key Employees
Grunenthal GmbH - Key Employee Biographies
Grunenthal GmbH - Major Products and Services
Grunenthal GmbH - Pharmaceutical Pipeline Products Data
Grunenthal GmbH, Pipeline Products by Therapy Area
Grunenthal GmbH, Pipeline Products by Development Phase
Grunenthal GmbH - History
Grunenthal GmbH - Company Statement
Grunenthal GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Grunenthal GmbH - Business Description
Grunenthal GmbH - Corporate Strategy
Grunenthal GmbH - SWOT Analysis
SWOT Analysis - Overview
Grunenthal GmbH - Strengths
Strength - Core Therapeutic Area: Pain Management
Strength - Focused Research and Development Activities
Strength - Robust Manufacturing Base
Grunenthal GmbH - Weaknesses
Weakness - Product Defects
Grunenthal GmbH - Opportunities
Opportunity - Growing Aged Population
Opportunity - Strategic Agreements
Opportunity - Market Potential: Pain
Grunenthal GmbH - Threats
Threat - Intense Competition
Threat - Government Regulations
Threat - Uncertain R&D Outcomes
Grunenthal GmbH - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Grunenthal GmbH, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Oct 20, 2014: Sascha Becker will join Grunenthal Group as new CFO
Sep 23, 2014: EFIC-Grunenthal Grant: Supporting up-and-Coming Researchers in the Field of Pain
Jun 17, 2014: Grünenthal presents new search fields at world’s largest biotechnology partnering conference

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Grunenthal GmbH, Key Facts
Grunenthal GmbH, Key Employees
Grunenthal GmbH, Key Employee Biographies
Grunenthal GmbH, Major Products and Services
Grunenthal GmbH, Number of Pipeline Products by Therapy Area
Grunenthal GmbH, Number of Pipeline Products by Development Stage
Grunenthal GmbH, Pipeline Products By Therapy Area and Development Phase
Grunenthal GmbH, History
Grunenthal GmbH, Other Locations
Grunenthal GmbH, Subsidiaries
Grunenthal GmbH, Key Competitors
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Grunenthal GmbH, Recent Deals Summary

LIST OF FIGURES

Grunenthal GmbH, Pipeline Products by Therapy Area
Grunenthal GmbH, Pipeline Products by Development Phase
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015
Skip to top


Nutricia GmbH - Strategic SWOT Analysis Review US$ 125.00 Feb, 2016 · 18 pages
VOCO GmbH - Strategic SWOT Analysis Review US$ 300.00 Feb, 2016 · 17 pages
TRACOE medical GmbH - Strategic SWOT Analysis Review US$ 125.00 Feb, 2016 · 19 pages

Ask Your Question

Grunenthal GmbH - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: